Clinical Trial Update: ZD6474 in Treating Patients With Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

The Phase 2 trial of ZD6474 for small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• ZD6474 (vandetanib)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED